Mike Sharma: Adding Antiplatelets to Anticoagulation in AF Increases Harm Without Benefit
Mike Sharma, Senior Scientist at Population Health Research Institute, reposted from JAMA Neurology on LinkedIn:
”Adding antiplatelets to anticoagulation in the setting of AF results in hazard without benefit. Now we’ll established in multiple studies. Where we lack data is in short term use following a cerebrovascular event that may be atherosclerotic in origin in patients with coexisting AF.”
Quoting JAMA Neurology‘s post:
”Editorial: The ATIS-NVAF trial shows adding antiplatelet therapy to OAC in stroke patients with AF and atherosclerotic disease increases major bleeding without significant reduction in ischemic events.”
Read the full article here.
Title: Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis
Authors: Richard A. Bernstein, Lauren E. Previch
Stay updated with Hemostasis Today.
-
Mar 18, 2026, 12:22Anita Brikman: Advancing Plasma-Derived Therapies in India Through Global Collaboration
-
Mar 18, 2026, 12:17Ben Samelson-Jones: Long-Term Safety and Efficacy of AAV Gene Therapy Using FIX-Padua in Hemophilia B
-
Mar 18, 2026, 12:14Sakditad Saowapa: Optimizing Sexual Activity and Minimizing Infection Risk in Patients with Neutropenia
-
Mar 17, 2026, 18:11Ossama Mansour: Landmark MENA Guidelines for Acute Ischemic Stroke Management
-
Mar 17, 2026, 17:48Andrea Van Beek: Improving DOAC Adherence Saves Lives
-
Mar 17, 2026, 17:43Soumen Bhattacharyya: Microangiopathic Hemolytic Anemia Is Often a Hematologic Clue to Underlying Malignancy
-
Mar 17, 2026, 17:37Peter Bou Dib: New Insights on Factor VIII and the Musculoskeletal System
-
Mar 17, 2026, 17:31Armghan Ans: The 2026 Stroke Guidelines Are Excellent, Now the Hard Part
-
Mar 17, 2026, 17:26Danny Hsu: Navigating a Rebalanced Hemostatic State in Decompensated Cirrhosis